BKY surges 15% as investor sentiment on uranium improves

|

Published 11-JAN-2017 15:07 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in emerging uranium producer, Berkeley Energia (ASX:BKY) performed strongly on Wednesday, trading as high as $1.19, representing a gain of approximately 15% compared with the previous day’s close of $1.03. While its share price has increased approximately 50% in the last month, it is worth noting that it is still trading at a sharp discount to analyst’s price targets.

However, it should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

David Talbot from Dundee Capital Markets recently highlighted the fact that the initially announced volumes had doubled to 2 million pounds over a five-year period and the average fixed-price may have increased slightly to US$43.78 per pound U308, at least from original guidance of US$41 per pound.

At the time the Binding Offtake Agreement with Interalloys was announced, Berkeley’s Chief Executive, Paul Atherley said, “We are delighted to have converted the previously announced Letter of Intent into a Binding Offtake Agreement, including the doubling of contract volumes, and with fixed pricing at US$43.78 per pound this gives us a very strong margin above our steady-state cash costs of around US$15.00 per pound”

Given this backdrop, Talbot maintained a buy recommendation and price target of $2.50, implying upside of more than 100% to the company’s current trading range.

Today’s rally could also be linked to improved sentiment towards the sector with more speculative players such as Deep Yellow and Paladin Energy spiking 18% and 6% respectively.

There is a perception that the near to medium-term outlook for uranium has improved and most analysts are tipping an uptick in prices is imminent.

Casting an eye across PCF Resources’ commodity projections over the next three years, uranium is expected to outperform leading precious metals such as gold and silver, all base metals, iron ore fines and oil.

The specialist resources analyst is forecasting uranium to increase from its current price of circa US$22 per pound to US$30 per pound in 2017 before increasing 50% to US$55 per pound in 2019.

Given that Berkeley’s Salamanca project located in Spain already sits at the bottom of the cost curve compared with its peers in terms of capital and operating costs, these projections suggest the company possesses compelling investment fundamentals with a margin of US$40.00 above steady-state cash costs implied by PCF’s 2019 forecasts.

News flow from the group has remained positive following the order of the first major items for the crushing circuit. In an encouraging development, the final cost of equipment ordered was more than 20% below estimates stated in the Definitive Feasibility Study (DFS).

Summing up these latest developments, Atherley said, “The lower costs and shorter lead time associated with this key phase of construction moves Berkeley closer to its goal of becoming one of the world’s lowest cost uranium producers, reliably supplying long-term customers from the heart of the European Union”.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X